Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis

Current Opinion in Rheumatology

Volumn 18, Issue 4, 2006, Pages 347-353

  Kavanaugh, Arthur ^a   Tutuncu, Zuhre ^a   Catalan Sanchez, Teresa ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ankylosing spondylitis; Anti tumor necrosis necrosis factor agents; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENTHESITIS; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; INFLAMMATION; JOINT RADIOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SPINE RADIOGRAPHY; SPONDYLOARTHROPATHY; TREATMENT OUTCOME; UVEITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; HUMANS; IMMUNOGLOBULIN G; MAGNETIC RESONANCE IMAGING; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLARTHRITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748045447     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.bor.0000231901.19795.8a     Document Type: Review

References (49)

1. Healy PJ, Helliwell PS. Classification of the spondyloarthropathies. Curr Opin Rheumatol 2005; 17:395-399.
2. Kane D, Stafford L, Bresnihan B, Fitzgerald D. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 2003; 42:1460-1468.
3. Chorus AMJ, Miedema HS, Boonen A, van der Linden S. Quality of life and work in patients with rheumatoid arthritis and ankylosing spondylitis of working age. Ann Rheum Dis 2003; 62:1178-1184.
4. van Dendern JC, van der Paar DT, Nurmohamed MT, et al. Double blind, randomized, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis 2005; 64:1761-1764. This recent article uses contemporary study design and outcome measures in assessing a traditional DMARD in patients with ankylosing spondylitis. The lack of efficacy observed provides support for that observed with other DMARDs in older studies.
5. Anandarajah A, Ritchlin CT. Treatment update on spondyloarthropathy. Curr Opin Rheumatol 2005; 17:247-256.
6. Davis JC Jr. Understanding the role of tumor necrosis factor inhibition in ankylosing spondylitis. Semin Arthritis Rheum 2004; 34:668-677.
7. van den Bosch F, Kruithof E, Baeten D, et al. Randomized double blind comparison of chimeric monoclonal antibody to tumor necrosis factor (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002; 46:755-765.
8. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002; 359:1187-1193.
9. Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003; 48:2224-2233.
10. Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005; 64:229-234.
11. Braun J, Baraliakos X, Brandt J, et al. Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology 2005; 44:670-676.
12. Baraliakos X, Listing J, Brandt J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 2005; 7:439-444.
13. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis. Arthritis Rheum 2005; 52:582-591. Another double-blind, placebo-controlled, randomized clinical trial, this study advances the use of newer outcome measures in studies of ankylosing spondylitis.
14. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002; 346:1349-1356.
15. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48:1667-1675.
16. Brandt J, Listing J, Haibel H, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 2005; 44:342-348.
17. Davis JC, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48:3230-3236.
18. Davis JC, Van der Heijde D, Braun J, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 2005; 64:1557-1562.
19. Davis JC, Van der Heijde D, Dougados M, et al. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005; 53:494-501.
20. Calin A, Dijkmans BAC, Emery P, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004; 63:1594-1600.
21. Davis J, Kivitz A, Schiff M, et al. Major clinical response and partial remission in ankylosing spondylitis subjects treated with adalimumab: the ATLAS trial. Arthritis Rheum 2005; 52 (Suppl 9):S208.
22. van der Heijde D, Luo M, Matsumoto A, et al. Adalimumab improves healthrelated quality of life in patients with active ankylosing spondylitis: the ATLAS trial. Arthritis Rheum 2005; 52 (Suppl 9):S211.
23. Braun J, van der Heidje D. Imaging and scoring in ankylosing spondylitis. Best Pract Res Clin Rheumatol 2002; 16:573-604.
24. Sieper J, Baraliakos X, Listing J, et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 years of treatment with the anti-tumor necrosis factor agent infliximab. Rheumatology 2005; 44:1525-1530.
25. Marzo-Ortega H, McGonagle D, Jarrett S, et al. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 2005; 64:1568-1575.
26. Baraliakos X, Davis J, Tsuji W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor α receptor fusion protein etanercept. Arthritis Rheum 2005; 52:1216-1223.
27. Rudwaleit M, Baraliakos X, Listing J, et al. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis 2005; 64:1305-1310.
28. Baraliakos X, Brandt J, Listing J, et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum (Arthritis Care Res) 2005; 53:856-863.
29. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with anti-tumor necrosis factor agents. Arthritis Rheum 2005; 52:2447-2451. This systematic review looks at the effect of TNF inhibitor therapy on uveitis, an important extra-articular manifestation of spondyloarthropathy.
30. Braun J, Pham T, Sieper J, et al. for the ASAS working group. International ASAS consensus statement for the use of anti-tumor necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62: 817-824.
31. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65:442-452. [Epub ahead of print].
32. Zochling J, van der Heidje D, Dougados M, et al. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006; 65:423-432. [Epub ahead of print].
33. Kruithof E, Baeten D, van den Bosch F, et al. Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis 2005; 64:529-536.
34. Kruithof E, De Rycke L, Roth J, et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondyloarthropathies. Arthritis Rheum 2005; 52:3898-3909.
35. Zou JX, Rudwaleit M, Brandt J, et al. Up regulation of the production of tumor necrosis factor α and interferon γ by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 2003; 62:561-564.
36. Zou JX, Rudwaleit M, Brandt J, et al. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 2003; 48:780-790.
37. Kavanaugh A, Cohen S, Cush J. The evolving use of TNF inhibitors in rheumatoid arthritis. J Rheumatol 2004; 31:1881-1884.
38. Kavanaugh A. Health economics: implications for novel antirheumatic therapies. Ann Rheum Dis 2005; 64 (Suppl IV):iv65-iv69.
39. Kavanaugh A, Kavanaugh A, Ritchlin C, and the GRAPPA Treatment Guideline Committee. Systematic review of treatments for psoriatic arthritis: an evidence-based approach and basis for treatment guidelines. J Rheumatol (in press).
40. Kavanaugh A, Cassell S. Outcome measures in psoriatic arthritis. Curr Rheumatol Rep 2005; 7:195-200.
41. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356:385-390.
42. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50:2264-2272.
43. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005; 52:1227-1236. The first study of infliximab in psoriatic arthritis, this paper establishes the agent's efficacy and sets the stage for further studies in this disease.
44. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005; 64:1150-1157.
45. Kavanaugh A, Antoni C, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006. [Epub ahead of print].
46. van der Heijde D, Gladman DD, Kavanaugh A, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis: 54 week result from IMPACT 2. Arthritis Rheum 2005; 52 (Suppl 9):S281.
47. Kavanaugh A, Antoni C, Krueger GG, et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann Rheum Dis 2006; 65:471-477. [Epub ahead of print].
48. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: result of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52:3279-3289.
49. Cassell S, Tutuncu Z, Kremer J, et al. Psoriatic arthritis patients have different rates of adverse events than rheumatoid arthritis patients when treated with TNF inhihitors: analysis from CORRONA Database. Arthritis Rheum 2005; 52 (Suppl 9):S211.